Search

Research

This study investigates the performance of an iteration of the Medtronic hybrid closed-loop algorithm

Research

We conclude that insulin pump therapy can be an effective tool to improve glycemic control in adolescents with long-standing treatment resistance

Research

This study reports similar glycemic outcomes for patients attending diabetes clinics in metropolitan and non-metropolitan areas of WA

Research

As the choices of therapies in diabetes care multiply, it is essential to standardize the approach to measuring and recording hypoglycemia risk

Research

Short-term studies with automated systems that suspend insulin when hypoglycemia is predicted have shown a reduction, but safety and efficacy aren't established

Research

Exposure to sunlight may limit cardiometabolic risk.

Research

Rapid improvements in glucose control may lead to early worsening of diabetic retinopathy (EWDR). There is a need to demonstrate safety in people commencing automated insulin delivery (AID) due to the known efficacy in rapid glycemic improvement. We aimed to investigate short-term DR outcomes in people (aged ≥13 years) with type 1 diabetes after initiation of AID (use ≥6 months).

Research

X linked hypophosphataemia (XLH) is a systemic, chronic condition that significantly impairs quality of life. In XLH, a phosphate regulating endopeptidase homologue X-linked (PHEX) gene mutation leads to excess fibroblast growth factor 23 (FGF23), causing hypophosphataemia and subsequent rickets, lower limb deformity, pain and other sequelae, however there are likely other non-FGF23 mediated mechanisms contributing to disease

Research

Globally, nearly 9 million people are living with type 1 diabetes (T1D). Although the incidence of T1D is not affected by socioeconomic status, the development of complications and limited access to modern therapy is overrepresented in vulnerable populations. Diabetes technology, specifically continuous glucose monitoring and automated insulin delivery systems, are considered the gold standard for management of T1D, yet access to these technologies varies widely across countries and regions, and varies widely even within high-income countries.

Research

To evaluate real-world glycaemic outcomes in children with type 1 diabetes commencing advanced hybrid closed loop therapy and to explore these outcomes based on the cohort's clinical and socioeconomic characteristics.